Life Sciences Tools & Services
IQVIA's revenue grew 8.7% year-over-year to $4,368 million in Q2 2026, driven by growth in both the Commercial Solutions and Research & Development Solutions segments, though segment profit growth was offset by higher restructuring costs and general corporate expenses, keeping consolidated segment profit flat at $506 million.
Key risk: Rising Interest Expense from Debt Refinancing
Interest expense increased to $197 million in Q2 2026 from $182 million in Q2 2025, and to $389 million for the six-month period from $347 million, driven by higher outstanding debt balances including new senior notes issuances. Total indebtedness reached $16,081 million as of June 30, 2026, which could pressure future earnings if rates or debt levels continue rising.
Other Life Sciences Tools & Services companies